RUNX1 and hemorrhagic disease: As TG studies have provided insights on other bleeding disorders, the major goal of our study was to determine if TG is impaired in a cohort with commonly encountered PFD, that included cases with nonsyndromic DGD and PFD with impaired aggregation responses to multiple agonists due to RUNX1 mutations or other uncharacterized molecular defects.